Nordhealth Valuation

Is NORDH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NORDH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NORDH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NORDH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NORDH?

Key metric: As NORDH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NORDH. This is calculated by dividing NORDH's market cap by their current revenue.
What is NORDH's PS Ratio?
PS Ratio	5.8x
Sales	€43.69m
Market Cap	€253.61m

NORDH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.3x
Enterprise Value/EBITDA	-148.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does NORDH's PS Ratio compare to its peers?

The above table shows the PS ratio for NORDH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.6x
CARA Carasent	5.5x	18.6%	NOK 1.4b
OMDA Omda	1.5x	6.9%	NOK 629.5m
CONTX ContextVision	2.7x	2.7%	NOK 369.8m
MEDI Medistim	4.7x	3.2%	NOK 2.5b
NORDH Nordhealth	5.8x	16.7%	NOK 3.0b

Price-To-Sales vs Peers: NORDH is expensive based on its Price-To-Sales Ratio (5.8x) compared to the peer average (3.6x).

Price to Sales Ratio vs Industry

How does NORDH's PS Ratio compare vs other companies in the European Healthcare Services Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: NORDH is expensive based on its Price-To-Sales Ratio (5.8x) compared to the European Healthcare Services industry average (2.2x).

Price to Sales Ratio vs Fair Ratio

What is NORDH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NORDH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.8x
Fair PS Ratio	2.8x

Price-To-Sales vs Fair Ratio: NORDH is expensive based on its Price-To-Sales Ratio (5.8x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.